Low cytotoxicity and high cellular gene delivery capability are among the most important prerequisites for the selection of a non-viral carrier. Although
calcium phosphate (CAP) nanoparticles have been long used for animal cell transfection, its rapid and uncontrollable crystal growth and lack of tissue specificity are among the most challenging problems that limit its use in the clinic. In this study, we report the development of CAP nanoparticles stabilized by a conjugate of the mussel-inspired adhesive molecule, 3,4-dihydroxy-l-phenylalanine (
dopa), and a nontoxic hydrophilic natural
polymer,
hyaluronic acid (HA), for targeted
siRNA delivery to
tumors. CAP/
siRNA/
dopa-HA can form compact nanoparticles that effectively protect
siRNA from enzymatic degradation despite the structural drawbacks of
siRNA, such as low charge density and short and rigid structure. In addition, stabilized CAP nanoparticles were able to maintain their colloidal stability in a physiological
salt condition for over a week. The superior ability of CAP/
siRNA/
dopa-HA to maintain the integrity of encapsulated
siRNA and the stability in
solution of the nanoparticles allow this formulation to achieve improved intratumoral accumulation of
siRNA and a high level of target gene silencing in solid
tumors after systemic administration. Considering its biocompatibility, transfection efficacy, and
tumor targeting capability, this stabilized
calcium phosphate nanoparticle-based gene delivery platform should be considered a promising candidate carrier for systemic
siRNA delivery and targeted
cancer therapy.